Pancreatic Cancer Research

ResearcherNihon UniversityActive in the last 2 years

Makoto Sano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6718-2353; OpenAlex author ID A5102722650, A5124724153, A5145781692. Sources: OpenAlex.

Their work

Papers
18 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 18

  1. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
  2. High-Dose Tramadol Enhances the Proliferative and Invasive Potential of Pancreatic Ductal Adenocarcinoma in Mice Through Microenvironmental Alteration. Co-author DOI 10.1155/prm/6594413↗
  3. Effects of cardiopulmonary bypass on in vitro proliferation of human pancreatic cancer cells and plasma growth factor levels. Co-author DOI 10.1186/s13019-026-03860-0↗
  4. Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer. First author DOI 10.1186/s40360-026-01176-2↗
  5. Duloxetine improves hyperosmia in mice with pancreatic cancer by increasing dopamine levels in the olfactory bulb. Co-author DOI 10.1016/j.biopha.2025.118098↗
  6. Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. Co-author DOI 10.1038/s41598-025-32222-4↗
  7. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Co-author DOI 10.1002/cam4.70124↗
  8. Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo. First author DOI 10.1136/rapm-2023-104511↗
  9. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors. Co-author DOI 10.1016/j.omto.2022.12.001↗
  10. Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer. First author DOI 10.1097/j.pain.0000000000002852↗
  11. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.bja.2021.12.042↗
  12. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  13. Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. First author DOI 10.1097/j.pain.0000000000001997↗
  14. Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT,… First author DOI 10.1016/j.tranon.2019.08.010↗
  15. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… Co-author DOI 10.1038/s41389-018-0117-8↗
  16. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo. Co-author DOI 10.1016/j.canlet.2017.03.031↗
  17. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. Co-author DOI 10.1016/j.neo.2016.11.004↗
  18. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideaki Ijichi · 14 shared papers, 2019–2026 · strength 2.64
  2. Tomoaki Itaya · 7 shared papers, 2022–2026 · strength 1.70
  3. Yukino Oshima · 7 shared papers, 2020–2026 · strength 1.47
  4. Tomoya Kuramochi · 6 shared papers, 2022–2026 · strength 1.36
  5. Yoshimi Ichimaru · 7 shared papers, 2017–2026 · strength 1.01
  6. Ichie Kajiwara · 6 shared papers, 2019–2026 · strength 1.01
  7. Takahiro Suzuki · 3 shared papers, 2026 · strength 0.95
  8. Takahiro Suzuki · 5 shared papers, 2020–2025 · strength 0.85
  9. Atsushi Masamune · 5 shared papers, 2020–2026 · strength 0.85
  10. Koji Miyabayashi · 4 shared papers, 2019–2026 · strength 0.68
  11. Gen Kimura · 3 shared papers, 2020–2026 · strength 0.60
  12. Mitsuhiro Fujishiro · 2 shared papers, 2025–2026 · strength 0.51
  13. Yohei Masugi · 2 shared papers, 2022–2026 · strength 0.38
  14. Kazuhiko Koike · 3 shared papers, 2019–2023 · strength 0.36
  15. Seidai Katagiri · 1 shared paper, 2026 · strength 0.33
  16. Tomoharu Yamada · 2 shared papers, 2019–2023 · strength 0.28
  17. Takahiro Kishikawa · 1 shared paper, 2025 · strength 0.27
  18. Genso Notoya · 1 shared paper, 2025 · strength 0.27
  19. Akiyoshi Hirayama · 1 shared paper, 2026 · strength 0.24
  20. Shingo Inaguma · 1 shared paper, 2024 · strength 0.20
  21. Yoichi Matsuo · 1 shared paper, 2024 · strength 0.20
  22. Hiroyuki Kato · 1 shared paper, 2024 · strength 0.20
  23. Akihisa Kato · 1 shared paper, 2024 · strength 0.20
  24. Satoru Takahashi · 1 shared paper, 2024 · strength 0.20
  25. Tomoki Todo · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.